Mankind Pharma, AI drug discovery, Denovo Sciences, artificial intelligence in healthcare, pharmaceutical innovation, and drug research are in focus after Mankind Pharma announced a strategic partnership with Denovo Sciences to develop an artificial intelligence-led drug discovery programme. The collaboration aims to accelerate early-stage research, improve the quality of drug candidates, and bring innovative therapies to patients more efficiently.

Under the partnership, Mankind Pharma will combine its research, experimental and clinical development capabilities with Denovo Sciences' proprietary AI platform for molecular generation and prioritisation. The companies aim to shorten drug discovery timelines by identifying the most promising molecular candidates at an early stage, enabling researchers to focus resources on compounds with higher potential for success.

A key feature of the collaboration is its human-in-the-loop approach, which integrates artificial intelligence with scientific expertise. While AI systems will generate, analyse and rank potential drug molecules using computational models, experienced researchers will validate, refine and guide the selection process throughout the discovery cycle. The companies believe this hybrid model will combine the speed and scale of AI with the critical judgement of scientists, improving decision-making and reducing the likelihood of advancing unsuitable candidates.

The partnership reflects the pharmaceutical industry's growing adoption of artificial intelligence to improve research productivity and reduce the time and cost associated with developing new medicines. By using AI to explore vast molecular datasets and identify promising compounds more efficiently, pharmaceutical companies hope to accelerate innovation while lowering the risks traditionally associated with early-stage drug development.

Mankind Pharma said the collaboration aligns with its long-term strategy of strengthening technology-driven research and development capabilities. The company believes integrating AI into its discovery pipeline will help create differentiated therapies while improving access to effective treatments for patients.

Denovo Sciences also described the collaboration as an opportunity to maximise the impact of artificial intelligence during the earliest stages of drug development, where better candidate selection can significantly reduce research costs and improve success rates.

Industry experts view the alliance as part of a broader shift toward AI-enabled pharmaceutical research. If successful, the partnership could accelerate the development of novel drug candidates for clinical trials and strengthen Mankind Pharma's position in India's innovation-driven pharmaceutical sector while enhancing its competitiveness in global healthcare markets.